Clinical Trial

Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.
Trial Details
NCT Number NCT06642857
Lead Sponsor Xiangdong Cheng
Conditions Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Enrollment 150 participants
Start Date 2024-03-25
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-15